Irbesartan Bgr (Irbesartan)

Irbesartan acts on the renin‑angiotensin‑aldosterone system to manage conditions related to elevated blood pressure and kidney disease.

• Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications.
• Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes.
• Chronic kidney disease with hypertension: improves blood pressure control and reduces proteinuria, supporting renal preservation.

• Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from binding and triggering vasoconstriction and aldosterone release. This inhibition leads to relaxation of vascular smooth muscle, reduced peripheral resistance, and decreased sodium and water retention, thereby lowering blood pressure and offering renal protective effects.

Irbesartan is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate intensity, often transient.
• Fatigue: feeling unusually tired or weak.
• Nausea: upset stomach or urge to vomit.
• Hyperkalemia: elevated blood potassium levels, usually mild.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or throat that may compromise breathing.
• Acute renal failure: sudden decline in kidney function, indicated by rising creatinine.
• Severe hyperkalemia: potassium levels markedly high, risking cardiac arrhythmia.
• Hepatic injury: abnormal liver enzymes or jaundice.
• Hypotension: excessive drop in blood pressure causing faintness.

Before initiating therapy, clinicians should consider several safety measures.

• Monitor blood pressure: ensure target levels are achieved without excessive drop.
• Assess renal function: check serum creatinine and eGFR periodically.
• Check serum potassium: especially when combined with potassium‑sparing agents.
• Use caution in hepatic impairment: dose adjustments may be required.
• Pregnancy and lactation: avoid use unless benefits outweigh risks, as safety data are limited.
• Store at room temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: combined use can increase risk of renal impairment and hyperkalemia.
• Dual blockade with ACE inhibitors or other ARBs: may cause excessive hypotension, renal dysfunction, and high potassium.
• Potassium‑sparing diuretics (e.g., spironolactone): heightens risk of severe hyperkalemia.

Moderate Interactions (Monitor Closely)

• NSAIDs (e.g., ibuprofen): can reduce antihypertensive effect and impair renal function.
• Lithium: may increase lithium concentrations, risking toxicity.
• Diuretics (thiazides): may enhance antihypertensive effect, requiring dose adjustment.
• CYP2C9 inhibitors (e.g., fluconazole): can raise irbesartan plasma levels modestly.